

Index

A

Afatinib, 9
AG-120, 72
AGI-5198, 71
AGI-6780, 71
Allograft, 30
AMPK, 124
Anaplasia, 172
Angiogenesis, 9
Annual incidence, 2
Anti-angiogenic therapy, 9
Anticancer agents, 97
Anti-ELTD1 treatment, 9
Antigenic, 100
Antisense therapies, 109
Apoptosis, 145
Area under the curve, 154
Artificial intelligence, 157
Astrocytes, 2
Astrocytomas, 172
ATP, 124
AZD9291, 9

B

Bevacizumab, 8, 81
BIRC5, 142
Bisdemethoxycurcumin, 141
Blood brain barrier, 4
Brain mapping, 187
Brain tumor-related epilepsy, 199

C

Cancer metabolism, 98
Cancer stem cells, 47
CCNU, 152
Cellular metabolism, 67, 68
CGGA, 153
Chemoradiation, 80
Chemotherapies, 64
Cholesterol derivatives, 97, 106, 107, 108
Cholesterol metabolism, 102
Classic glioblastoma, 174
Classification, 100
Clinical practice, 174
Clinical presentation, 121, 203
Clinical trials, 177, 182
Comparative dosimetry, 88
Computational approaches, 153, 159
Concordance index, 154
Convolutional neural network, 157, 189
Cox's proportional hazards model, 154
Cre-LoxP, 20, 21, 23
CRISPR/Cas9, 26
Curcumin, 139
Current challenges, 175

D

D-2HG, 63, 66
Deep learning, 157
Desmoplastic infantile astrocytoma, 212
Diffuse gliomas, 172

Digital pathology, 162
DIPG, 54, 85
Direct electrical stimulation, 188
DS-1001b, 72

E

EGFR, 9, 174
EGFR/HER1, 8
ELTD1, 1
Energy metabolism, 121, 123
Ependymoma, 54
Epidemiology, 99, 200
Epigenetic alternations, 66
Epigenomic repression, 69

F

Functional modules, 176
Future directions, 171, 176

G

Gangliocytoma, 212
Ganglioglioma, 212
Gap junctions, 202
Gefitinib, 9
Genetic changes, 51
Genetic characteristics, 100
Genetic characterization, 162
GL261, 1,8
Glioblastoma, 1, 5, 97, 102, 121, 152, 173
Glioblastoma-associated edema, 128
Glioma cell lines, 145
Glioma patients, 79
Gliomagenesis, 124
Gliomas, 54, 139, 151, 171
Glioneuronal tumors, 211
Grade I-IV, 172

Gross resection, 80
Growth, 61
GTP synthesis pathways, 127

H

High-grade glioma, 152
Histone methylation, 66
Humanized mouse models, 34

I

IDH, 61, 63, 64, 70
IGF-IR, 109
Imaging, 160, 213
Immune checkpoint therapy, 30
Immunocompromised mice, 33
IMP dehydrogenase, 127
IMPDH2, 128
In utero electroporation, 85
Inflammation, 128
Ionizing radiation, 80
Isocitrate dehydrogenase 1, 61, 100

J

Junction complexes, 5

K

Karnofsky performance
status, 152

L

Late effects, 219, 221
Left hemisphere, 191
Lipo-neurocytoma, 212
Liver X Receptors, 104
Lower grade gliomas, 152

M

m⁶A, 66
Machine learning, 154
Magnetic resonance imaging, 157
Malignancy, 126
Management, 199, 203
Medulloblastoma, 52
Mesenchymal glioblastoma, 174
Metabolic characterization, 63
Metabolic reprogramming, 126
Metabolic therapy, 97
Metabolism, 61, 101
MGMT, 70, 100, 152
Mitochondria, 108
MMF, 127
Model validation, 154
Molecular analysis, 79
Molecular characterization, 162, 217
Molecular genetics, 202
Molecular markers, 171
Molecular profile, 174
Mouse models, 15, 79, 84
Mycophenolate mofetil, 127
Mycophenolic acid, 127

N

N⁶-methyladenosine, 66
Nanotherapy, 109
Neoangiogenesis, 129
Neural glioblastoma, 174
Neural stem cells, 2
Neuropsychological testing, 187
Neurotransmitters, 202
NF1, 174
NOD/SCID, 6
Non-coding RNA, 83
Non-diffuse gliomas, 172

Notch/DLL4, 9
Novel approaches, 151
NRF2, 143

O

O⁶-methylguanine-DNA methyltransferase, 100, 152
Obesity-associated protein, 66
OKN-007, 10
Oligodendrocytes, 2
Osimertinib, 9
Outcomes, 79
Oxidative stress, 145
Oxysterols, 106

P

Papillary glioneuronal tumor, 212
Paradoxical outcomes, 69
Paraganglioma, 212
Pathogenesis, 100, 199, 200
Pathology, 216
Patient derived orthotopic xenograft, 7
PDGFRA, 174
Pediatric brain tumors, 47
Pediatric, 55
Peritumoral environmental changes, 202
Personalized medicine, 83
Pre-clinical models, 1, 5
Primary glioblastoma, 2
Procarbazine, 152
Prognosis, 171
Prognostic classes, 152
Proneural glioblastoma, 174
Prospective trials, 155
Proton beam therapy, 87
Proton therapy, 79
PTEN, 2, 100, 174

Q

qPCR, 82, 144
Qualitative analysis, 5
Quality of life, 89, 192, 193, 200
Quercetin, 106
Quiescence, 53

R

Radiation therapy, 125, 126, 220
Radiation, 64
Radiomics, 159
Random forest, 157, 158
RANK, 143
Real-time, 187
Receiver operating characteristics curve, 154
Recurrent surgery, 195
Recursive partitioning analysis, 154
Redox status, 65
Response to treatment, 161
Right hemisphere, 191
Risk factors, 100
RNA-based therapies, 84
RNA-binding proteins, 104

S

SCID mice, 6
Secondary glioblastoma, 2
Seizures, 201
Single-cell RNA-sequencing, 82
Sonic hedgehog, 51
SREBP, 105
Standardization of methods, 180
Statins, 105
Stereotactic radiosurgery, 87
Stress resilience, 69

Stresses, 124
Stroke-associated edema, 128
Stupp protocol, 80
Support vector machine, 157, 158
Surgical management, 206, 219
Surgical treatment, 204
Survival prediction, 151
Symptom control, 219
Systemic therapy, 145

T

T2FLAIR, 161
Targeting energy metabolism, 121
TCGA, 152
Technical challenge, 68
Temozolomide, 81, 152
TERT, 174
The Cancer Genome Atlas, 152
The Cancer Imaging Archive, 161
Therapeutic efficacy, 64
Therapeutic resistance, 121
Therapeutic sensitivity, 70
Therapeutics, 8, 61
Therapy-limiting factors, 3
Toxicity, 142
TP53, 100, 174
Transforming growth factor β 1, 10
Transposons, 24, 25
Treating pediatric brain tumors, 56
Treatment options, 82
Treatment resistance, 50
Tumor growth rate, 201
Tumor invasiveness, 144
Tumor location, 201
Tumor microenvironment, 30
Tumor resection, 187
Tumor treating fields, 64

Tumor treating fields, 81
Tumor-associated edema, 121
Tumorigenesis, 9
Turmeric, 141

U

Ubiquitin ligase, 104
Ubiquitination, 144

V

Validation, 191
Vascular endothelial growth factor, 2
Vincristine, 152
Viral vector delivery system, 28

W

WHO 2016 classification, 172
Whole brain radiation therapy, 30
Wnt, 143

X

Xenograft mouse models, 5

Y

Young patients, 195

Z

Zebra fish, 129

Doi: <https://doi.org/10.36255/exonpublications.gliomas.2021.index>

